O
IPXL

OrbiMed’s Impax Laboratories, Inc. IPXL Stock Holding History

OrbiMed’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3,787,500
Closed -$89.8M – 147
2016
Q3 		$89.8M Sell
3,787,500
-2,099,200
-36% -$56.4M 1.02% 36
2016
Q2 		$170M Sell
5,886,700
-889,400
-13% -$29M 1.77% 18
2016
Q1 		$217M Buy
6,776,100
+112,000
+2% +$3.94M 2.28% 11
2015
Q4 		$285M Hold
6,664,100
– – 2.58% 12
2015
Q3 		$235M Sell
6,664,100
-75,100
-1% -$3.38M 2.37% 11
2015
Q2 		$309M Buy
6,739,200
+61,200
+0.9% +$2.9M 2.59% 12
2015
Q1 		$313M Hold
6,678,000
– – 2.67% 11
2014
Q4 		$212M Buy
6,678,000
+272,800
+4% +$7.98M 2.02% 16
2014
Q3 		$152M Buy
6,405,200
+989,600
+18% +$25.4M 1.59% 25
2014
Q2 		$162M Buy
5,415,600
+70,000
+1% +$1.89M 1.91% 21
2014
Q1 		$141M Buy
5,345,600
+1,108,000
+26% +$27.7M 1.74% 23
2013
Q4 		$107M Buy
4,237,600
+951,900
+29% +$21.2M 1.57% 23
2013
Q3 		$67.3M Buy
3,285,700
+25,100
+0.8% +$518K 1.2% 27
2013
Q2 		$65M Buy
+3,260,600
New +$57.9M 1.38% 29

Other funds holding IPXL

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

OrbiMed's IPXL Position: Q4 2016 in Review

OrbiMed sold out of Impax Laboratories, Inc. (IPXL) in Q4 2016, closing a stake of 3,787,500 shares — an estimated $89.8M sold.

OrbiMed first reported a position in IPXL in Q2 2013 and held it in 14 quarters. The position peaked at $313M in Q1 2015. 198 funds tracked by Wall St. Rank hold IPXL as of Q4 2016.

  • OrbiMed reported no remaining Impax Laboratories, Inc. position as of Q4 2016 after selling out during the quarter.
  • OrbiMed sold 3,787,500 Impax Laboratories, Inc. shares in Q4 2016, an estimated $89.8M.
  • OrbiMed first reported a position in Impax Laboratories, Inc. in Q2 2013 and held it in 14 quarters.
  • OrbiMed's Impax Laboratories, Inc. position peaked at $313M in Q1 2015.
  • 198 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q4 2016.

Based on OrbiMed's 13F filing for Q4 2016, filed 14 Feb 2017.